Ro 6-3129

Ro 6-3129, also known as 16α-ethylthio-6-dehydroretroprogesterone or as 16α-ethylthio-9β,10α-pregna-4,6-diene-3,20-dione, as well as 16α-ethylthiodydrogesterone, is a progestogen of the retroprogesterone group which was developed by Roche but was never marketed.[1][2][3] It shows greater potency than dydrogesterone in bioassays.[4]

Ro 6-3129
Clinical data
Other names16α-Ethylthiodydrogesterone; 16α-Ethylthio-6-dehydroretroprogesterone; 16α-Ethylthio-9β,10α-pregna-4,6-diene-3,20-dione
Routes of
administration		Oral
Identifiers
ChemSpider
Chemical and physical data
FormulaC23H32O2S
Molar mass372.57 g·mol−1
3D model (JSmol)

References
  1. JUCKER (8 March 2013). Progress in Drug Research / Fortschritte der Arzneimittelforschung / Progrès des rechersches pharmaceutiques. Birkhäuser. pp. 321–. ISBN 978-3-0348-7098-6.
  2. Larsson-Cohn U, Johansson ED, Wide L, Gemzell C (1970). "Effects of daily administration of a retrosteroid on the plasma levels of progesterone and on the urinary excretion of luteinizing hormone and total oestrogens". J Obstet Gynaecol Br Commonw. 77 (9): 840–6. PMID 5458777.
  3. Dixon, Ross; Hudson, Sean; Darragh, Austin (1973). "Pharmacokinetics of the retro-steroid progestogen, 16α-ethylthio-9β,10α-pregna-4, 6-diene-3, 20-dione (Ro 6-3129), in man and the sheep". Contraception. 8 (1): 53–65. doi:10.1016/0010-7824(73)90159-5. ISSN 0010-7824.
  4. The Journal of Obstetrics and Gynaecology of the British Commonwealth. Royal College of Obstetricians and Gynaecologists. 1970.



This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.